

AINNOCENCE LAUNCHES CellulaAI™: A Pioneering AI Engine to Revolutionize CAR-T Therapy

BIRMINGHAM, ALABAMA, UNITED STATES, September 3, 2024

/EINPresswire.com/ -- [Ainnocence](#) Inc., a leader in AI-driven biotech solutions, is proud to announce the launch of [CellulaAI™](#), an innovative AI engine designed to transform the landscape of CAR-T therapy. By harnessing the power of artificial intelligence, CellulaAI™ optimizes every aspect of the CAR-T design and production process, paving the way for safer, more effective, and personalized cancer treatments worldwide.

CellulaAI™ is built on a robust framework that enhances the efficacy, safety, and scalability of CAR-T therapies. This next-generation AI system integrates advanced computational methods to streamline and accelerate key processes in the development of CAR-T cells, offering unparalleled precision and insight at every stage.

Key Features of CellulaAI™:

- **Target Antigen Identification:** Accurately identifies the most effective antigens to target cancer cells with high specificity.
- **ScFv Design and Optimization:** Engineers single-chain variable fragments (ScFv) for superior binding affinity and stability.
- **Costimulatory Domains Selection:** Chooses the optimal costimulatory domains to enhance T-



CellulaAI™
Cell Programming AI Engine

CellulaAI™ represents a cutting-edge AI system that leverages the power of artificial intelligence to transform CAR-T therapy. By optimizing every aspect of the CAR-T design and production process, this engine aims to bring safer, more effective, and personalized cancer treatments to patients worldwide.

- ✓ Enhanced Efficacy
- ✓ Personalization
- ✓ Improved Safety
- ✓ Scalability

Key Components:

- 🔍 Target Antigen Identification
- 🧬 ScFv Design and Optimization
- 🔥 Costimulatory Domains Selection
- 🛡️ Off-target and Immunogenicity Screen
- 🧪 In Silico Testing and Validation
- 🏭 Manufacturing and Scalability Insights

CellulaAI™, an innovative AI engine designed to transform the landscape of CAR-T therapy.



The graphic features a dark teal background with a white diagonal line. On the right, there are four diamond-shaped images: a hand holding a vial, a microscopic view of cells, a doctor and patient, and a globe. The Ainnocence logo is in the top right corner.

cell activation and persistence.

- Off-target and Immunogenicity Screening: Performs comprehensive in silico screenings to minimize off-target effects and immunogenicity risks.
- In Silico Testing and Validation: Simulates and validates the efficacy and safety of CAR-T designs before clinical trials.

Revolutionizing CAR-T Therapy:

CellulaAI™ represents a significant breakthrough in the quest for more personalized and effective cancer treatments. By optimizing the design and production of CAR-T cells, this AI engine not only improves patient outcomes but also accelerates the development pipeline, reducing costs and time to market.

One of the key advantages of CellulaAI™ is its unparalleled ability to optimize binding specificity against a broad group of antigens. This capability surpasses what other computational engines can achieve, making it possible to target a wider array of cancer cells with greater precision. This specificity not only enhances the effectiveness of the therapy but also reduces potential side effects, offering a safer treatment option for patients.

"We believe that CellulaAI™ is a game-changer in the field of CAR-T therapy," said Lurong Pan, CEO of Ainnocence. "Our AI-driven approach brings a new level of precision and efficiency to cell programming, ultimately offering patients safer and more personalized treatment options."

About Ainnocence:

Ainnocence is revolutionizing drug discovery with our next-generation, self-evolving AI platform. We offer unparalleled speed and precision in virtual screening and pharmacological profile optimization for various therapeutic modalities.

For more information about CellulaAI™, visit www.ainnocence.com. To schedule a demo, please [contact](#) us.

COPYRIGHT © 2024 INNOCENCE INC. ALL RIGHTS RESERVED.

ALL GREAT TRUTHS ARE SIMPLE.

Lurong Pan, PhD
CEO and Founder, Ainnocence
+1 205-249-7424
service@ainnocence.com

This press release can be viewed online at: <https://www.einpresswire.com/article/740130749>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.